{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T05:42:53Z","timestamp":1793943773822,"version":"4.8.0"},"reference-count":41,"publisher":"American Society of Hematology","issue":"16","license":[{"start":{"date-parts":[[2022,5,5]],"date-time":"2022-05-05T00:00:00Z","timestamp":1651708800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,10,20]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>There is a growing body of evidence that therapy-related myeloid neoplasms (t-MNs) with driver gene mutations arise in the background of clonal hematopoiesis (CH) under the positive selective pressure of chemo- and radiation therapies. Uncovering the exposure relationships that provide selective advantage to specific CH mutations is critical to understanding the pathogenesis and etiology of t-MNs. In a systematic analysis of 416\u00a0patients with t-MN and detailed prior exposure history, we found that TP53 mutations were significantly associated with prior treatment with thalidomide analogs, specifically lenalidomide. We demonstrated experimentally that lenalidomide treatment provides a selective advantage to Trp53-mutant hematopoietic stem and progenitor cells (HSPCs) in\u00a0vitro and in\u00a0vivo, the effect of which was specific to Trp53-mutant HSPCs and was not observed in HSPCs with other CH mutations. Because of the differences in CK1\u03b1 degradation, pomalidomide treatment did not provide an equivalent level of selective advantage to Trp53-mutant HSPCs, providing a biological rationale for its use in patients at high risk for t-MN. These findings highlight the role of lenalidomide treatment in promoting TP53-mutated t-MNs and offer a potential alternative strategy to mitigate the risk of t-MN development.<\/jats:p>","DOI":"10.1182\/blood.2021014956","type":"journal-article","created":{"date-parts":[[2022,5,5]],"date-time":"2022-05-05T15:00:36Z","timestamp":1651762836000},"page":"1753-1763","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":151,"title":["Lenalidomide promotes the development of\n                    <i>TP53<\/i>\n                    -mutated therapy-related myeloid neoplasms"],"prefix":"10.1182","volume":"140","author":[{"given":"Adam S.","family":"Sperling","sequence":"first","affiliation":[{"name":"1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"},{"name":"2Division of Hematology, Brigham and Women\u2019s Hospital, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronica A.","family":"Guerra","sequence":"additional","affiliation":[{"name":"3Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James A.","family":"Kennedy","sequence":"additional","affiliation":[{"name":"1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"},{"name":"4Department of Medicine, University of Toronto, Toronto, Canada"},{"name":"5Division of Hematology and Medical Oncology, Princess Margaret Cancer Centre, University Health Network, Toronto, Canada"},{"name":"6Division of Hematology and Medical Oncology, Sunnybrook Health Sciences Centre, Toronto, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanqing","family":"Yan","sequence":"additional","affiliation":[{"name":"7Department of Neurosurgery, University of Northwestern, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanne I.","family":"Hsu","sequence":"additional","affiliation":[{"name":"8Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Wang","sequence":"additional","affiliation":[{"name":"9Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew T.","family":"Nguyen","sequence":"additional","affiliation":[{"name":"1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter G.","family":"Miller","sequence":"additional","affiliation":[{"name":"1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie E.","family":"McConkey","sequence":"additional","affiliation":[{"name":"1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa A.","family":"Quevedo Barrios","sequence":"additional","affiliation":[{"name":"2Division of Hematology, Brigham and Women\u2019s Hospital, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Furudate","sequence":"additional","affiliation":[{"name":"3Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX"},{"name":"10Department of Oral and Maxillofacial Surgery, Hirosaki University Graduate School of Medicine, Hirosaki, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Zhang","sequence":"additional","affiliation":[{"name":"8Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rashmi","family":"Kanagal-Shamanna","sequence":"additional","affiliation":[{"name":"11Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianhua","family":"Zhang","sequence":"additional","affiliation":[{"name":"9Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Latasha","family":"Little","sequence":"additional","affiliation":[{"name":"9Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Curtis","family":"Gumbs","sequence":"additional","affiliation":[{"name":"9Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naval","family":"Daver","sequence":"additional","affiliation":[{"name":"3Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Courtney D.","family":"DiNardo","sequence":"additional","affiliation":[{"name":"3Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tapan","family":"Kadia","sequence":"additional","affiliation":[{"name":"3Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farhad","family":"Ravandi","sequence":"additional","affiliation":[{"name":"3Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hagop","family":"Kantarjian","sequence":"additional","affiliation":[{"name":"3Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillermo","family":"Garcia-Manero","sequence":"additional","affiliation":[{"name":"3Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. Andrew","family":"Futreal","sequence":"additional","affiliation":[{"name":"9Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin L.","family":"Ebert","sequence":"additional","affiliation":[{"name":"1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"},{"name":"12Howard Hughes Medical Institute, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Takahashi","sequence":"additional","affiliation":[{"name":"3Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX"},{"name":"9Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"1","key":"2022121921582367000_bib1","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1182\/blood-2002-11-3343","article-title":"Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago series","volume":"102","author":"Smith","year":"2003","journal-title":"Blood"},{"issue":"9","key":"2022121921582367000_bib2","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/nrc.2017.60","article-title":"Therapy-related myeloid neoplasms: when genetics and environment collide","volume":"17","author":"McNerney","year":"2017","journal-title":"Nat Rev Cancer"},{"issue":"5","key":"2022121921582367000_bib3","doi-asserted-by":"crossref","first-page":"E80","DOI":"10.1002\/ajh.23966","article-title":"Characteristics and outcome of therapy-related myeloid neoplasms: report from the Italian network on secondary leukemias","volume":"90","author":"Fianchi","year":"2015","journal-title":"Am J Hematol"},{"issue":"1","key":"2022121921582367000_bib4","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1182\/asheducation.V2016.1.24.088333","article-title":"Therapy-related myeloid neoplasms: does knowing the origin help to guide treatment?","volume":"2016","author":"Heuser","year":"2016","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"6","key":"2022121921582367000_bib5","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1056\/NEJMoa1611604","article-title":"Prognostic mutations in myelodysplastic syndrome after stem-cell transplantation","volume":"376","author":"Lindsley","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"2022121921582367000_bib6","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.stem.2018.10.004","article-title":"PPM1D mutations drive clonal hematopoiesis in response to cytotoxic chemotherapy","volume":"23","author":"Hsu","year":"2018","journal-title":"Cell Stem Cell"},{"issue":"9","key":"2022121921582367000_bib7","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1182\/blood-2014-11-610543","article-title":"Acute myeloid leukemia ontogeny is defined by distinct somatic mutations","volume":"125","author":"Lindsley","year":"2015","journal-title":"Blood"},{"issue":"7540","key":"2022121921582367000_bib8","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/nature13968","article-title":"Role of TP53 mutations in the origin and evolution of therapy-related acute myeloid leukaemia","volume":"518","author":"Wong","year":"2015","journal-title":"Nature"},{"issue":"1","key":"2022121921582367000_bib9","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/S1470-2045(16)30626-X","article-title":"Preleukaemic clonal haemopoiesis and risk of therapy-related myeloid neoplasms: a case-control study","volume":"18","author":"Takahashi","year":"2017","journal-title":"Lancet Oncol"},{"issue":"1","key":"2022121921582367000_bib10","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/S1470-2045(16)30627-1","article-title":"Clonal haemopoiesis and therapy-related myeloid malignancies in elderly patients: a proof-of-concept, case-control study","volume":"18","author":"Gillis","year":"2017","journal-title":"Lancet Oncol"},{"issue":"14","key":"2022121921582367000_bib11","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1200\/JCO.2016.71.6712","article-title":"Clonal hematopoiesis associated with adverse outcomes after autologous stem-cell transplantation for lymphoma","volume":"35","author":"Gibson","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"2022121921582367000_bib12","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.stem.2017.07.010","article-title":"Therapy-related clonal hematopoiesis in patients with non-hematologic cancers is common and associated with adverse clinical outcomes","volume":"21","author":"Coombs","year":"2017","journal-title":"Cell Stem Cell"},{"issue":"20","key":"2022121921582367000_bib13","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"issue":"9","key":"2022121921582367000_bib14","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1038\/nbt.2951","article-title":"Generation of mouse models of myeloid malignancy with combinatorial genetic lesions using CRISPR-Cas9 genome editing","volume":"32","author":"Heckl","year":"2014","journal-title":"Nat Biotechnol"},{"issue":"14","key":"2022121921582367000_bib15","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1182\/blood-2018-05-852798","article-title":"Crbn (I391V) is sufficient to confer in vivo\u00a0sensitivity to thalidomide and its derivatives in mice","volume":"132","author":"Fink","year":"2018","journal-title":"Blood"},{"issue":"12","key":"2022121921582367000_bib16","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1182\/blood.2020009103","article-title":"Modeling and targeting of erythroleukemia by hematopoietic genome editing","volume":"137","author":"Iacobucci","year":"2021","journal-title":"Blood"},{"issue":"4","key":"2022121921582367000_bib17","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/nmeth865","article-title":"Quantitative production of macrophages or neutrophils ex vivo using conditional Hoxb8","volume":"3","author":"Wang","year":"2006","journal-title":"Nat Methods"},{"issue":"1","key":"2022121921582367000_bib18","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.cell.2016.08.057","article-title":"Inhibition of dihydroorotate dehydrogenase overcomes differentiation blockade in acute myeloid leukemia","volume":"167","author":"Sykes","year":"2016","journal-title":"Cell"},{"issue":"10","key":"2022121921582367000_bib19","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1038\/s41591-020-1008-z","article-title":"Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes","volume":"26","author":"Bernard","year":"2020","journal-title":"Nat Med"},{"issue":"23","key":"2022121921582367000_bib20","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","article-title":"Genomic classification and prognosis in acute myeloid leukemia","volume":"374","author":"Papaemmanuil","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"19","key":"2022121921582367000_bib41","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1200\/JCO.2011.38.7340","article-title":"Acute myeloid leukemia and myelodysplastic syndromes after radiation therapy are similar to de novo disease and differ from other therapy-related myeloid neoplasms","volume":"30","author":"Nardi","year":"2012","journal-title":"J Clin Oncol"},{"issue":"15","key":"2022121921582367000_bib21","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1200\/JCO.2010.31.8576","article-title":"TP53 mutations in low-risk myelodysplastic syndromes with del(5q) predict disease progression","volume":"29","author":"Jadersten","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"issue":"7559","key":"2022121921582367000_bib22","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1038\/nature14610","article-title":"Lenalidomide induces ubiquitination and degradation of CK1\u03b1 in del(5q) MDS","volume":"523","author":"Kr\u00f6nke","year":"2015","journal-title":"Nature"},{"issue":"5","key":"2022121921582367000_bib23","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1158\/2643-3230.BCD-20-0224","article-title":"ZBTB33 is mutated in clonal hematopoiesis and myelodysplastic syndromes and impacts RNA splicing","volume":"2","author":"Beauchamp","year":"2021","journal-title":"Blood Cancer Discov"},{"issue":"6","key":"2022121921582367000_bib24","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.cell.2004.11.004","article-title":"Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome","volume":"119","author":"Olive","year":"2004","journal-title":"Cell"},{"issue":"7597","key":"2022121921582367000_bib25","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/nature16979","article-title":"Structural basis of lenalidomide-induced CK1\u03b1 degradation by the CRL4CRBN ubiquitin\u00a0ligase","volume":"532","author":"Petzold","year":"2016","journal-title":"Nature"},{"issue":"2","key":"2022121921582367000_bib26","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1182\/blood.2019000789","article-title":"Patterns of substrate affinity, competition, and degradation kinetics underlie biological activity of thalidomide analogs","volume":"134","author":"Sperling","year":"2019","journal-title":"Blood"},{"issue":"4","key":"2022121921582367000_bib27","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1084\/jem.20131033","article-title":"Csnk1a1 inhibition has p53-dependent therapeutic efficacy in acute myeloid leukemia","volume":"211","author":"Jaras","year":"2014","journal-title":"J\u00a0Exp Med"},{"issue":"4","key":"2022121921582367000_bib28","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.ccr.2014.08.001","article-title":"Role of casein kinase 1A1 in the biology and targeted therapy of del(5q) MDS","volume":"26","author":"Schneider","year":"2014","journal-title":"Cancer Cell"},{"issue":"5","key":"2022121921582367000_bib29","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1002\/cpdd.869","article-title":"First-in-human, single- and multiple-ascending-dose studies in healthy subjects to assess pharmacokinetics, pharmacodynamics, and safety\/tolerability of iberdomide, a novel cereblon E3 ligase modulator","volume":"10","author":"Ye","year":"2021","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"6453","key":"2022121921582367000_bib30","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1126\/science.aax3649","article-title":"A dominant-negative effect drives selection of TP53 missense mutations in myeloid malignancies","volume":"365","author":"Boettcher","year":"2019","journal-title":"Science"},{"issue":"7","key":"2022121921582367000_bib31","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1038\/s41375-018-0351-2","article-title":"TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups","volume":"33","author":"Haase","year":"2019","journal-title":"Leukemia"},{"issue":"7714","key":"2022121921582367000_bib32","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1038\/s41586-018-0317-6","article-title":"Prediction of acute myeloid leukaemia risk in healthy individuals","volume":"559","author":"Abelson","year":"2018","journal-title":"Nature"},{"issue":"7","key":"2022121921582367000_bib33","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1038\/s41591-018-0081-z","article-title":"Somatic mutations precede acute myeloid leukemia years before diagnosis","volume":"24","author":"Desai","year":"2018","journal-title":"Nat Med"},{"issue":"11","key":"2022121921582367000_bib34","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1038\/s41588-020-00710-0","article-title":"Cancer therapy shapes the fitness landscape of clonal hematopoiesis","volume":"52","author":"Bolton","year":"2020","journal-title":"Nat Genet"},{"issue":"5","key":"2022121921582367000_bib35","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1038\/s41556-020-0497-9","article-title":"Loss of lenalidomide-induced megakaryocytic differentiation leads to therapy resistance in del(5q) myelodysplastic syndrome","volume":"22","author":"Martinez-Hoyer","year":"2020","journal-title":"Nat Cell Biol"},{"issue":"1","key":"2022121921582367000_bib36","doi-asserted-by":"crossref","first-page":"2996","DOI":"10.1038\/s41467-020-16805-5","article-title":"Clonal hematopoiesis is associated with adverse outcomes in multiple myeloma patients undergoing transplant","volume":"11","author":"Mouhieddine","year":"2020","journal-title":"Nat Commun"},{"issue":"15","key":"2022121921582367000_bib37","doi-asserted-by":"crossref","first-page":"2996","DOI":"10.1182\/blood-2012-08-448068","article-title":"Evolving risk of therapy-related acute myeloid leukemia following cancer chemotherapy among adults in the United States, 1975-2008","volume":"121","author":"Morton","year":"2013","journal-title":"Blood"},{"issue":"1","key":"2022121921582367000_bib38","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/s41467-018-02858-0","article-title":"Cellular stressors contribute to the expansion of hematopoietic clones of varying leukemic potential","volume":"9","author":"Wong","year":"2018","journal-title":"Nat Commun"},{"issue":"4","key":"2022121921582367000_bib39","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.stem.2010.03.002","article-title":"p53-mediated hematopoietic stem and progenitor cell competition","volume":"6","author":"Bondar","year":"2010","journal-title":"Cell Stem Cell"},{"issue":"11","key":"2022121921582367000_bib40","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1182\/blood-2018-05-850339","article-title":"PPM1D-truncating mutations confer resistance to chemotherapy and sensitivity to PPM1D inhibition in hematopoietic cells","volume":"132","author":"Kahn","year":"2018","journal-title":"Blood"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/140\/16\/1753\/1927479\/blood_bld-2021-014956-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/140\/16\/1753\/1927479\/blood_bld-2021-014956-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,19]],"date-time":"2022-12-19T16:58:44Z","timestamp":1671469124000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/140\/16\/1753\/485177\/Lenalidomide-promotes-the-development-of-TP53"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,20]]},"references-count":41,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2022,10,20]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2021014956","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,20]]}}}